Monthly Fund Commentary - Sep 2017


Global Titans Fund commentary

September seemed like a case of Deja vu with November of last year. The “Trump Trade”, full of hopes for a more robust economy, ignited again as the topic of tax reform came front and centre. The Emerging markets led, and other developed markets modestly outperformed the US. Economic indicators globally continue to point to solid growth, supporting earnings growth and market sentiment. The Fed announced it will finally begin unwinding quantitative easing, allowing maturing debt to gradually roll off the balance sheet—news that markets met with indifference.

The sector relative returns after the election, from November 8 to November 29 of last year, nearly mirrored returns from September 8 to September 29 of this year. The cyclical sectors outperformed the defensive sectors this time led by the energy and materials sectors, as commodity prices rallied, and the more defensive health care and consumer staples sectors trailed. Similar to November 2016 the financials significantly outperformed and bond-proxy sectors underperformed.

The Fund’s unit price increased by 0.8%, after the cost of protection, in September. As discussed cyclical stocks significantly outperformed quality stocks with the extreme moves mirroring last year’s Trump rally. The fund performance was driven by positive contributions from our holdings in eBay, Paypal, Visa, Cognizant Tech Solutions and Amadeus IT. The main negative contributors were Medtronic, Reckitt Benckiser, Oracle, Comcast and Heineken.

The Fund continues to have no foreign currency hedging in place as Insync consider the main risks to the Australian dollar to be on the downside. Over 50% of the Fund is currently protected using our put protection strategy.

Top 10 holdings

  • Heineken

  • Microsoft

  • Visa

  • Unilever

  • Reckitt Benckiser

  • Comcast

  • PayPal

  • Cognizant Tech Solutions

  • eBay

  • Oracle

Stryker – Disrupting the status quo

Disruption is a megatrend and is a key part of assessing today’s investment landscape. Disruptive forces are accelerating across many industries and is even creating change in old established industries where innovation has been relatively minimal. One example is the orthopaedics industry, which mainly consists of hip and knee implants, which has operated in a stable and highly profitable industry structure primarily split between 4 players. There has been limited product differentiation over a long period of time with no provider gaining more that 1.5% market share over the past 8 years.

Insync believe that Stryker’s robotic platform has the potential to be highly disruptive which has the potential to break the market share stalemate between the major players. Robotic-assisted surgery has the greatest likelihood to drive share gains as it has the potential to deliver consistent results through improved alignment and soft tissue management. The main reason for using a robotic system is to be able to hit very accurately a target that varies from patient to patient. It is particularly useful in knees because they are more problematic (than hips) and a large proportion of patients that aren’t satisfied with their knee replacement. In fact, satisfaction rates are only around 65 percent for knee operations, against 95 percent for hips, according to industry surveys.

Stryker’s management have an excellent track record in making capital allocation decisions. It has increased its dividend every year for 24 consecutive years. This degree of success hinges on strong acquisitions, consistent profitability, and a diverse revenue stream that shelters the company from single-point failures. The ageing population provides a long run way of growth and Stryker’s first mover advantage in robotics should enable it to take market share and drive profits and dividends well into the future.

About Us

PORTFOLIO CHARACTERISTICS

Average market cap A$189.3bn

WAVG⁴ forecast dividend yield 1.50%

Wt AVG forecast PE ratio 20.3x

WAVG ROE 21.0%

Current FX hedging position 0% overseas exposure hedged back into $A

Current put protection 50%

Benchmark Unconstrained

KEY INFORMATION

APIR code SLT0041AU

ASX mFund code INS01

Distributions paid Annually, as at 30 June

Unit pricing Daily

Minimum initial investment $10,000

Applications & redemptions Each Sydney business day

Entry & exit fee Nil

Buy/Sell spread 0.20%/0.20%

MER 1.3% (plus GST) p.a.

Investment style

Concentrated, large cap global equity fund, incorporating active currency management and downside protection strategies

Investment objectives

To provide long term capital growth and some income through investment in listed global securities. Insync believes that a strong focus on capital preservation will lead to superior relative and absolute returns over time

How to apply

Apply online here.

#MonthlyFundCommentary

  • LinkedIn Social Icon
  • YouTube Social  Icon

©2018 by Insync Funds Management Pty Ltd.

Disclaimer

The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person’s particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.